Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

A quick roundup episode of major news and health policy developments from The American Journal of Managed Care.

Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.

Combining physician education with patient previsit activation increases deprescribing of diabetes medications, according to one study.